Entera Bio Ltd Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $42K-76.8% YoYTTM through 30 Jun 2026
Net Income -$11.4MTTM through 30 Jun 2026
Free Cash Flow -$11MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 0.0% |
| Operating Margin | -27,450.0% |
| Net Margin | -27,235.7% |
Returns
-87.0%ROE
-71.3%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio8.98x
Net Debt-$12Mnet cash position
Cash & Equivalents$11.3M
Quality Metrics
Altman Z-Score14.64
Piotroski F-Score3 / 9
FCF Margin-26,100.0%
Earnings-Beat Rate100.0%
Multi-Year Trend
RevenueFY2025: $42K
Diluted EPS-$0.35TTMFY2025: $0.25
Dividend
No dividend
Capital Allocation
R&D Spend$8.8M
Capex Intensity173.8%
Segment Performance
No segment data available.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.